3 completed, 1 not yet recruiting, 1 withdrawn. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 2 |
Follow Complicated Urinary Tract Infections: new trials by email Literature Review of Complicated Urinary Tract Infections trials Research Report on Complicated Urinary Tract Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cefepime/Enmetazobactam for Bacteremic Complicated Urinary Tract Infections Complicated Urinary Tract Infections, Antibiotic Resistance | Not yet recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 200 | 2026-10-15 | 2026-07-24 | |
| LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI) LYS228, Standard of care therapy - Complicated Urinary Tract Infections | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2018-10-19 | 2018-10-26 | |
| Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults Sulopenem, Sulopenem-Etzadroxil/Probenecid, Ertapenem - Complicated Urinary Tract Infections | Phase 3 | Completed | Iterum Therapeutics, International Limited | 1395 | 2018-09-18 | 2020-12-29 |
| Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections Eravacycline, Ertapenem, Placebo - Complicated Urinary Tract Infections | Phase 3 | Completed | Tetraphase Pharmaceuticals, Inc | 1205 | 2017-01-01 | 2022-01-06 |
| Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs) Ceftazidime -avibactam, Cefepime - Complicated Urinary Tract Infections | Phase 2 | Completed | Pfizer | 97 | 2015-09-24 | 2018-07-11 |
Bacteremia (1) · Urinary Tract Infections (1)
Infections (2) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Inflammation (1) · Male Urogenital Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Sepsis (1) · Systemic Inflammatory Response Syndrome (1) · Urogenital Diseases (1) · Urologic Diseases (1)
Ertapenem (2) · Amoxicillin-Potassium Clavulanate Combination (1) · Cefepime (1) · Ciprofloxacin (1) · Levofloxacin (1) · Probenecid (1) · avibactam, ceftazidime drug combination (1) · eravacycline (1) · sulopenem (1)
IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Iterum Therapeutics, International Limited (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · Tetraphase Pharmaceuticals, Inc (1)
United States (4) · Hungary (3) · Estonia (2) · Georgia (2) · Greece (2) · Latvia (2) · Romania (2) · Russia (2) · Austria (1) · Bulgaria (1) · Czechia (1) · Denmark (1) · Italy (1) · Moldova (1) · Poland (1)
Cecilia Maria Bonazzetti, MD (1)
PMID 30061293, PMID 31335570, PMID 34687548, PMID 36068705
2014 (1)